NCT06050044View on ClinicalTrials.gov

Intrathecal Injection of Hyperbaric Bupivacaine Versus a Mixture of Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Lower Abdominal Surgery

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Spinal AnesthesiaHyperbaric BupivacaineIsobaric BupivacaineLower Abdominal Surgery
Interventions
DRUG

Group A (hyperbaric bupivacaine)

Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution

DRUG

Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)

Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution

Trial Locations (1)

Unknown

Helwan University, Helwan

All Listed Sponsors
lead

Helwan University

OTHER